evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

116 questions · 124 findings · 25 reviews · Infectious Diseases

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 5.6%GRADE not reported 6 · 4.8%Very low 24 · 19.4%Low 55 · 44.4%Moderate 21 · 16.9%High 11 · 8.9%

Intervention not reported

All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with artesunate‐amodiaquine (AS‐AQ) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with mefloquine plus artesunate (MQ + AS) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) may leads to lower total failure: day 28 (unadjusted) compared with artemether‐lumefantrine (AL) (low certainty).

2 findings from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review